Alzheimer's and diabetes have much in common, including many risk factors and underlying pathological mechanisms. It stands to reason that treatments which might be helpful for diabetics might also be helpful for Alzheimer's patients.

First clinical data of the neuroprotective effects of nasal insulin application in patients with Alzheimer's disease
Previous reviews have outlined the important role of insulin in the brain, and the observation that insulin signaling is desensitized in patients with Alzheimer's disease (AD). Because insulin is used
Glucose intolerance, insulin resistance, and pathological features of alzheimer disease in the baltimore longitudinal study of aging
IMPORTANCE: Peripheral glucose homeostasis has been implicated in the pathogenesis of Alzheimer disease (AD). The relationship among diabetes mellitus, insulin, and AD is an important area of investi
Inhaled Insulin for Alzheimer's Disease: Phase II Clinical Trial Results -- Overview
The recent results from a clinical trial of insulin for the treatment of AD has garnered a great deal of media attention. Before discussing the research, it is worth reviewing insulin's role in the br
Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence
Research in animals and humans has associated Alzheimer’s disease (AD) with decreased cerebrospinal fluid levels of insulin in combination with decreased insulin sensitivity (insulin resistance) in th
Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment -- A Pilot Clinical Trial
Objective: To examine the effects of intranasal insulin administration on cognition, function, cerebral glucose metabolism, and cerebrospinal fluid biomarkers in adults with amnestic mild cognitive i
Intranasal treatment of central nervous system dysfunction in humans
One of the most challenging problems facing modern medicine is how to deliver a given drug to a specific target at the exclusion of other regions. For example, a variety of compounds have beneficial e
Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease
A previous clinical trial demonstrated that four months of treatment with intranasal insulin improves cognition and function for patients with Alzheimer's disease (AD) or mild cognitive impairment (MC